CD388
CD388 is an antiviral reagent-Fc conjugate formed by linking an influenza virus neuraminidase inhibitor to the CH1-Fc hybrid domain of IgG1. CD388 exerts antiviral activity extracellularly by inhibiting Neuraminidase. CD388 reduces pulmonary viral load and proinflammatory cytokine levels in influenza-infected mice, prevents death, reduces body weight loss, and prolongs median time to death. CD388 exhibits activity against influenza A and B subtypes, including highly pathogenic strains. CD388 can be used in influenza-related research.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 分子式: CD388
- 分子量:793.48
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
製品説明
体外実験
CD388 (0.001 pM-10000 nM; 3 days (influenza A), 5 days (influenza B)) potently inhibits the cytopathic effect of MDCK/MDCK-SIAT1 cells infected with influenza A and influenza B viruses, with median EC50 values ranging from 0.80 nM to 1.72 nM and a selectivity index of >1000-fold[3].
CD388 potently neutralizes highly pathogenic avian influenza (HPAI) A/H5N1 and A/H7N9 viruses in MDCK cells, with median half-maximal effective concentrations (EC50) of 0.57 nM and 0.04 nM, respectively[3].
CD388 (0.001-1000 nM; 20 min) potently inhibits recombinant influenza neuraminidase (NA) from various A/H5N1, A/H7N9 and CDC reference strains (including NAI-resistant variants), with IC50 values ranging from 0.12 to 7.63 nM, and shows minimal loss of activity against drug-resistant variants[4].
CD388 (0.001 pM-10000 nM; 3 days for influenza A, 5 days for influenza B) potently inhibits influenza A strains A/H1N1, A/H3N2 and influenza B strains in the cytopathic effect (CPE) assay using MDCK/MDCK-SIAT1 cells, with median EC50 values of 0.80 nM, 1.27 nM and 1.72 nM, respectively[4].
CD388 (0.00001 nM-10,000 nM; 24 h-5 days) exhibits no cytotoxicity toward primary lung fibroblasts, PBMC, HEp-2 cells, and A549 cells, with a CC50 greater than 10,000 nM and a selectivity index greater than 1000[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:primary human lung fibroblast (HLF) cells, peripheral blood mononuclear cells (PBMCs), HEp-2 cells, and A549 cells
-
Concentration:0.00001 nM-10,000 nM
-
Incubation Time:24 h (HLF/PBMCs); 5 days (HEp-2/A549 cells)
-
Result:Had a half-maximal cytotoxic concentration (CC50) of >10,000 nM in all tested human cell types, resulting in a >1,000-fold selectivity index relative to its antiviral EC50 values.
Parmacokinetics
| Species | Dose | Route | Tmax | Cmax | T1/2 | AUC0-t | CL/F | Vz/F |
|---|---|---|---|---|---|---|---|---|
| Rat[2] | 146 (14C-CD388) mg/kg | s.c. | 24 h | 440.1 μg/mL | 190 h | 114700 μg·h/mL | 1.191 mL/h/kg | 326.5 mL/kg |
体内実験
CD388 (0.03-3 mg/kg; i.m.; single dose) provides full survival protection against lethal influenza A/Puerto Rico/8/1934 (H1N1) challenge in BALB/c mice at a single 0.3 mg/kg i.m. dose, with dose-dependent reductions in lung viral burden and pro-inflammatory cytokines[3].
CD388 (1 mg/kg; i.m.; single dose; 7 days pre-challenge) provides full prophylactic survival protection against lethal challenge with multiple influenza A and B strains in BALB/c mice at a single 1 mg/kg i.m. dose administered 7 days pre-exposure[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c mice (immune competent)[1]
-
Dosage:0.3 mg/kg; 1 mg/kg
-
Administration:i.m.; single dose
-
Result:Provided 100% survival across all tested influenza subtypes at ≤1 mg/kg.
Achieved minimum fully protective dose of 1 mg/kg for H1N1 (7 isolates) and B (Victoria) (2 isolates), and 0.3 mg/kg for H3N2 (1 isolate) and B (Yamagata) (1 isolate).
Caused transient BW loss (5-15% of starting weight) before recovery.
-
Animal Model:BALB/c SCID (female, 6-8 weeks of age, intranasal challenge with 3×LD95 of mouse-adapted influenza A/Puerto Rico/8/1934 (H1N1))[3]
-
Dosage:1 mg/kg
-
Administration:i.m.; single dose
-
Result:Provided full survival protection.
化学情報
-
分子量 793.48
-
分子式 CD388
-
SMILES
[2H]C([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])([2H])[2H]
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
[2]. Laenen A, et al. Absorption, distribution, metabolism, and excretion of an antiviral drug-Fc conjugate CD388 following subcutaneous administration of C-CD388 in the rat. Drug metabolism and disposition: the biological fate of chemicals. 2025 Jul;53(7):100103. [Content Brief]
[4]. Döhrmann S, et al. Drug-Fc conjugate CD388 targets influenza virus neuraminidase and is broadly protective in mice. Nature microbiology. 2025 Apr;10(4):912-926. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
CD388 関連分類
HY-185821 関連分類
Powered by Bioz